{
    "hands_on_practices": [
        {
            "introduction": "A drug's therapeutic action begins with its binding to a molecular target. This fundamental interaction is governed by the law of mass action, which relates drug concentration, receptor affinity, and the fraction of receptors occupied. This first exercise guides you through the derivation of the core receptor occupancy equation and its application to a selective serotonin reuptake inhibitor (SSRI), connecting a foundational biophysical principle to a tangible clinical benchmark for antidepressant efficacy .",
            "id": "4509090",
            "problem": "A selective serotonin reuptake inhibitor at steady state binds the serotonin transporter (SERT) with rapid reversible kinetics and a single high-affinity binding site. Consider the fundamental reversible binding scheme between free receptor and free ligand: $R + L \\rightleftharpoons RL$. The dissociation constant is defined by equilibrium mass action as $K_{d} \\equiv \\frac{[R][L]}{[RL]}$, where $[R]$ is the free receptor concentration, $[L]$ is the free drug concentration at the site of action, and $[RL]$ is the drug-receptor complex concentration. The total receptor concentration is $R_{T} = [R] + [RL]$. Define the receptor occupancy as the fraction of receptors bound by ligand, $\\theta \\equiv \\frac{[RL]}{R_{T}}$. Assume that the free drug concentration at the site equals the unbound synaptic concentration $C$, that binding is at equilibrium, and that the single-site model applies.\n\nIn a patient receiving a serotonin transporter inhibitor, posit that the free synaptic concentration is $C = 10$ nM and the dissociation constant for SERT is $K_{d} = 2$ nM. It is widely observed in positron emission tomography (PET) studies that a clinical response threshold corresponds to an occupancy of approximately $0.8$.\n\nStarting only from the definitions above, derive an expression for $\\theta$ in terms of $C$ and $K_{d}$ and use it to compute the occupancy for the given $C$ and $K_{d}$. Then quantify the margin above the clinical response threshold by computing $\\Delta \\equiv \\theta - 0.8$. Report the final requested value $\\Delta$ as an exact fraction (unitless). Do not express any result as a percentage. If you choose to present a decimal in intermediate reasoning, do not round the final answer; present it exactly as a fraction.",
            "solution": "The problem statement is evaluated as valid. It is scientifically grounded in the principles of receptor pharmacology, specifically the law of mass action applied to reversible ligand-receptor binding. The problem is well-posed, providing all necessary definitions, constants, and conditions to derive a unique solution. The language is objective and quantitative, and the parameters given ($C = 10 \\text{ nM}$, $K_{d} = 2 \\text{ nM}$) are realistic for a high-affinity drug-target interaction. The problem structure allows for a direct and logical derivation.\n\nThe primary task is to derive an expression for receptor occupancy, $\\theta$, and then use it to compute the margin, $\\Delta$, above a specified clinical threshold.\n\nWe are given the following definitions and relationships:\n1. Reversible binding equilibrium: $R + L \\rightleftharpoons RL$\n2. Dissociation constant: $K_{d} = \\frac{[R][L]}{[RL]}$\n3. Total receptor concentration: $R_{T} = [R] + [RL]$\n4. Receptor occupancy: $\\theta = \\frac{[RL]}{R_{T}}$\n5. The free ligand concentration, $[L]$, is equated to the free synaptic drug concentration, $C$, so $[L] = C$.\n\nOur goal is to derive an expression for $\\theta$ in terms of $C$ and $K_{d}$. We begin with the definition of occupancy:\n$$ \\theta = \\frac{[RL]}{R_{T}} $$\nSubstitute the definition of $R_{T}$ into the equation for $\\theta$:\n$$ \\theta = \\frac{[RL]}{[R] + [RL]} $$\nTo proceed, we must express the unknown concentrations, $[R]$ and $[RL]$, in terms of the known quantities $C$ and $K_d$. We can use the definition of the dissociation constant to relate $[R]$ to $[RL]$. Substituting $[L] = C$ into the expression for $K_d$:\n$$ K_{d} = \\frac{[R]C}{[RL]} $$\nWe rearrange this equation to solve for the free receptor concentration, $[R]$:\n$$ [R] = \\frac{K_{d}[RL]}{C} $$\nNow, we substitute this expression for $[R]$ back into our equation for $\\theta$:\n$$ \\theta = \\frac{[RL]}{\\left(\\frac{K_{d}[RL]}{C}\\right) + [RL]} $$\nThe concentration of the receptor-ligand complex, $[RL]$, appears in every term in the fraction. We can factor $[RL]$ out of the denominator:\n$$ \\theta = \\frac{[RL]}{[RL]\\left(\\frac{K_{d}}{C} + 1\\right)} $$\nSince we are considering a case where drug is present ($C > 0$), there will be some binding, meaning $[RL] > 0$. Therefore, we can safely cancel the $[RL]$ term from the numerator and the denominator:\n$$ \\theta = \\frac{1}{\\frac{K_{d}}{C} + 1} $$\nTo simplify this complex fraction, we multiply the numerator and denominator by $C$:\n$$ \\theta = \\frac{C \\cdot 1}{C \\cdot \\left(\\frac{K_{d}}{C} + 1\\right)} = \\frac{C}{K_{d} + C} $$\nThis is the required expression for receptor occupancy. It is a form of the Hill-Langmuir equation for a system with a single ligand binding to a single receptor site.\n\nNext, we compute the value of $\\theta$ using the given values: $C = 10 \\text{ nM}$ and $K_{d} = 2 \\text{ nM}$. The units (nM) are consistent and will cancel, yielding a dimensionless occupancy value.\n$$ \\theta = \\frac{10}{2 + 10} = \\frac{10}{12} $$\nSimplifying this fraction, we get:\n$$ \\theta = \\frac{5}{6} $$\nThe problem requires us to quantify the margin, $\\Delta$, above the clinical response threshold of $0.8$, defined as $\\Delta = \\theta - 0.8$. To maintain exactness as requested, we convert the decimal $0.8$ to a fraction:\n$$ 0.8 = \\frac{8}{10} = \\frac{4}{5} $$\nNow we compute $\\Delta$ using the fractional values:\n$$ \\Delta = \\frac{5}{6} - \\frac{4}{5} $$\nTo perform the subtraction, we find a common denominator, which for $6$ and $5$ is $30$:\n$$ \\Delta = \\frac{5 \\cdot 5}{6 \\cdot 5} - \\frac{4 \\cdot 6}{5 \\cdot 6} = \\frac{25}{30} - \\frac{24}{30} $$\nThis gives the final result for $\\Delta$:\n$$ \\Delta = \\frac{1}{30} $$",
            "answer": "$$\\boxed{\\frac{1}{30}}$$"
        },
        {
            "introduction": "Once a drug occupies its target receptor, the next step is the generation of a physiological response. The relationship between drug concentration and the magnitude of its effect is captured by the Emax model, which formally links receptor binding theory to the observable effects of a drug. In this practice, you will use this model to calculate the concentration required to achieve a specific level of biological effect and delve into the concept of intrinsic efficacy, which distinguishes different classes of agonists .",
            "id": "4509085",
            "problem": "A psychoactive therapeutic that acts as an agonist at a central nervous system receptor exhibits a monotonic hyperbolic concentration–effect relationship consistent with mass-action binding and proportional transduction under conditions of negligible receptor reserve. The half-maximal effective concentration ($EC_{50}$) is defined as the concentration at which the observed effect equals one-half of the drug’s own maximal effect and is measured to be $20$ nM for this agonist. Assume that the effect $E$ scales linearly with the fraction of occupied receptors and that the half-maximal effective concentration ($EC_{50}$) equals the equilibrium dissociation constant ($K_D$) under these assumptions.\n\nUsing only the above definitions and fundamental receptor-binding principles (law of mass action and the fraction-occupancy expression), determine the agonist concentration $C$ required to achieve $0.70$ of its own maximal effect. Round your answer to four significant figures and express the final concentration in nanomolar (nM).\n\nThen, based on first principles, explain how partial agonism modifies the maximal effect $E_{\\text{max}}$ relative to the system’s maximal possible response and whether the concentration you computed depends on the absolute magnitude of $E_{\\text{max}}$ under the stated assumptions.",
            "solution": "The problem is first validated to ensure it is scientifically grounded, well-posed, and objective.\n\n**Step 1: Extract Givens**\n- The concentration-effect relationship is monotonic and hyperbolic.\n- The mechanism is consistent with mass-action binding and proportional transduction.\n- The system has negligible receptor reserve.\n- The half-maximal effective concentration ($EC_{50}$) is the concentration for one-half of the drug’s own maximal effect.\n- $EC_{50} = 20$ nM.\n- The effect $E$ scales linearly with the fraction of occupied receptors.\n- Under these assumptions, $EC_{50}$ equals the equilibrium dissociation constant ($K_D$).\n- The target effect is $0.70$ of the drug's own maximal effect, $E_{\\text{max}}$.\n- The final answer for concentration $C$ should be rounded to four significant figures and expressed in nanomolar (nM).\n- An explanation is required for how partial agonism modifies $E_{\\text{max}}$ and whether the computed concentration $C$ depends on the absolute magnitude of $E_{\\text{max}}$.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is valid. It describes a standard, simplified model of receptor pharmacology based on the law of mass action (the Hill-Langmuir equation). The premises are scientifically sound, the terminology is precise, and the provided data ($EC_{50}$) are sufficient and consistent for determining the required concentration. The problem is well-posed and directly relevant to the field of neuropharmacology.\n\n**Step 3: Verdict and Action**\nThe problem is valid and a solution will be provided.\n\n**Part 1: Calculation of Agonist Concentration**\n\nThe binding of a single agonist molecule, which we denote by concentration $C$, to a single receptor site $R$ to form an agonist-receptor complex $CR$ can be represented by the equilibrium reaction:\n$$C + R \\rightleftharpoons CR$$\nAccording to the law of mass action, the equilibrium dissociation constant, $K_D$, is defined as:\n$$K_D = \\frac{[C][R]}{[CR]}$$\nThe total concentration of receptors, $[R_T]$, is the sum of the concentration of free receptors, $[R]$, and the concentration of occupied receptors, $[CR]$:\n$$[R_T] = [R] + [CR]$$\nThe fractional occupancy, $\\theta$, is the ratio of the concentration of occupied receptors to the total concentration of receptors:\n$$\\theta = \\frac{[CR]}{[R_T]}$$\nWe can express $[R]$ as $[R] = [R_T] - [CR]$ and substitute this into the expression for $K_D$:\n$$K_D = \\frac{[C]([R_T] - [CR])}{[CR]}$$\nThis equation can be rearranged to solve for the fractional occupancy $\\theta$. First, we solve for $[CR]$:\n$$K_D [CR] = [C][R_T] - [C][CR]$$\n$$K_D [CR] + [C][CR] = [C][R_T]$$\n$$[CR](K_D + [C]) = [C][R_T]$$\n$$\\frac{[CR]}{[R_T]} = \\frac{[C]}{K_D + [C]}$$\nThus, the fractional occupancy is:\n$$\\theta = \\frac{C}{K_D + C}$$\nwhere we replace $[C]$ with the simpler notation $C$.\n\nThe problem states that the observed effect, $E$, scales linearly with the fraction of occupied receptors. This implies a direct proportionality:\n$$E = k \\cdot \\theta$$\nwhere $k$ is a constant of proportionality representing the intrinsic efficacy and total receptor number. The maximal effect for this specific agonist, $E_{\\text{max}}$, is achieved when all receptors are occupied (i.e., at saturating concentration, where $\\theta \\to 1$). Therefore, $E_{\\text{max}} = k \\cdot 1 = k$. Substituting $k$ with $E_{\\text{max}}$, the concentration-effect relationship becomes:\n$$E = E_{\\text{max}} \\cdot \\theta = E_{\\text{max}} \\frac{C}{K_D + C}$$\nThis is the hyperbolic concentration-effect equation. The problem states that for this system, the half-maximal effective concentration, $EC_{50}$, is equal to the equilibrium dissociation constant, $K_D$. This is consistent with the derived equation, as setting $C = K_D$ gives $E = E_{\\text{max}} \\frac{K_D}{K_D + K_D} = E_{\\text{max}} \\frac{K_D}{2 K_D} = \\frac{1}{2} E_{\\text{max}}$.\nWe are given $EC_{50} = 20$ nM, so we have $K_D = 20$ nM.\n\nWe need to find the concentration $C$ that produces an effect equal to $0.70$ of the maximal effect. That is, $E = 0.70 \\cdot E_{\\text{max}}$. We set up the equation:\n$$0.70 \\cdot E_{\\text{max}} = E_{\\text{max}} \\frac{C}{K_D + C}$$\nThe term $E_{\\text{max}}$ cancels from both sides:\n$$0.70 = \\frac{C}{K_D + C}$$\nWe now solve for $C$:\n$$0.70 (K_D + C) = C$$\n$$0.70 \\cdot K_D + 0.70 \\cdot C = C$$\n$$0.70 \\cdot K_D = C - 0.70 \\cdot C$$\n$$0.70 \\cdot K_D = C (1 - 0.70)$$\n$$0.70 \\cdot K_D = 0.30 \\cdot C$$\n$$C = \\frac{0.70}{0.30} K_D = \\frac{7}{3} K_D$$\nSubstituting the given value $K_D = 20$ nM:\n$$C = \\frac{7}{3} (20 \\text{ nM}) = \\frac{140}{3} \\text{ nM}$$\nCalculating the numerical value and rounding to four significant figures:\n$$C \\approx 46.666... \\text{ nM} \\approx 46.67 \\text{ nM}$$\n\n**Part 2: Explanation of Partial Agonism and Dependence on $E_{\\text{max}}$**\n\nFirst-principles of receptor theory distinguish agonists based on their intrinsic efficacy ($\\epsilon$), a measure of the ability of the drug-receptor complex to produce a response. The total response $E$ is a function of receptor occupancy and efficacy. A simplified model is $E = \\epsilon \\cdot [R_T] \\cdot \\theta$.\n\nPartial agonism refers to the behavior of an agonist that possesses intermediate intrinsic efficacy. Even when it occupies all available receptors (saturating concentration, $\\theta=1$), it cannot elicit the maximal possible response that the biological system is capable of producing. The maximal effect for a partial agonist ($E_{\\text{max, partial}}$) is therefore lower than the system's maximal response ($E_{\\text{system\\_max}}$), which is defined by the action of a full agonist (a drug with high intrinsic efficacy). In summary, partial agonism modifies (reduces) the maximal effect, $E_{\\text{max}}$, of the drug itself, such that $0 < E_{\\text{max, partial}} < E_{\\text{system\\_max}}$.\n\nRegarding the second question, the calculation performed to find the concentration $C$ does **not** depend on the absolute magnitude of $E_{\\text{max}}$. As shown in the derivation, the target effect was set as a fraction of the drug's own maximal effect ($E = 0.70 \\cdot E_{\\text{max}}$). In the resulting equation:\n$$0.70 \\cdot E_{\\text{max}} = E_{\\text{max}} \\frac{C}{K_D + C}$$\nthe term $E_{\\text{max}}$ cancels out. The final expression for the concentration, $C = \\frac{7}{3} K_D$, depends only on the receptor affinity ($K_D$) and the desired fractional response ($0.70$). Therefore, under the stated assumptions of proportional transduction and negligible receptor reserve, any agonist (full or partial) with a $K_D$ of $20$ nM would require the exact same concentration ($46.67$ nM) to achieve $70\\%$ of its own, specific maximal effect, regardless of whether that maximal effect is large (full agonist) or small (partial agonist).",
            "answer": "$$\n\\boxed{46.67}\n$$"
        },
        {
            "introduction": "Achieving the desired therapeutic effect requires maintaining an optimal drug concentration at the target site over time, a challenge addressed by the principles of pharmacokinetics. Individual genetic variations, such as those affecting metabolic enzymes like CYP2D6, can dramatically alter drug clearance and require tailored dosing strategies. This final practice places you in a realistic clinical setting where you must integrate pharmacokinetic and pharmacogenetic principles to calculate a personalized dose for a patient, ensuring both drug efficacy and safety .",
            "id": "4509034",
            "problem": "A clinician is adjusting the regimen for a tricyclic antidepressant (TCA) in a patient with a cytochrome P450 2D6 (CYP2D6) ultrarapid metabolizer phenotype. Assume linear pharmacokinetics with one-compartment, first-order elimination, attainment of steady state, and unchanged oral bioavailability between phenotypes.\n\nIn an extensive metabolizer reference population, a once-daily regimen of dose $D_{\\mathrm{EM}}$ equal to $96$ mg every $24$ h achieves an average steady-state plasma concentration at the midpoint of the standard therapeutic window of $100$–$300$ ng/mL. For this reference, the oral bioavailability is $F=0.50$ and the systemic clearance is $CL_{\\mathrm{EM}}=10$ L/h.\n\nFor the current patient with a CYP2D6 ultrarapid metabolizer phenotype, the TCA clearance increases $3.0$-fold relative to the extensive metabolizer reference, while the oral bioavailability remains $F=0.50$ and the dosing interval remains $\\tau=24$ h. Due to comorbid conduction disease and the use of a sodium channel–active co-medication, the acceptable therapeutic window is narrowed to $120$–$180$ ng/mL. The clinical goal is to target the midpoint of this narrowed window.\n\nUsing only well-tested pharmacokinetic relationships and these data, compute the adjusted total oral dose per $24$ h needed for this ultrarapid metabolizer to achieve the average steady-state concentration at the midpoint of the narrowed window. Round your final numeric answer to three significant figures and express the total daily dose in mg.",
            "solution": "First, the problem statement is validated to ensure its scientific and logical integrity.\n\n**Step 1: Extract Givens**\n- **Model Assumptions**: Linear pharmacokinetics, one-compartment model, first-order elimination, attainment of steady state, and oral bioavailability ($F$) is constant across phenotypes.\n- **Extensive Metabolizer (EM) Reference Population**: A once-daily regimen with dose $D_{\\mathrm{EM}} = 96$ mg and dosing interval $\\tau = 24$ h. The oral bioavailability is $F=0.50$ and systemic clearance is $CL_{\\mathrm{EM}}=10$ L/h. This regimen achieves an average steady-state plasma concentration ($\\bar{C}_{\\mathrm{ss,EM}}$) at the midpoint of the therapeutic window of $100\\text{--}300$ ng/mL.\n- **Ultrarapid Metabolizer (UM) Patient**: The systemic clearance ($CL_{\\mathrm{UM}}$) is $3.0$-fold greater than $CL_{\\mathrm{EM}}$. The oral bioavailability remains $F=0.50$ and the dosing interval remains $\\tau=24$ h. The acceptable therapeutic window is narrowed to $120\\text{--}180$ ng/mL. The clinical objective is to target the average steady-state concentration ($\\bar{C}_{\\mathrm{ss,UM}}$) at the midpoint of this narrowed window.\n- **Task**: Compute the adjusted total oral dose per $24$ h ($D_{\\mathrm{UM}}$) for the UM patient, expressed in mg and rounded to three significant figures.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded in established principles of pharmacokinetics. The use of a one-compartment model with first-order elimination at steady state is a standard approach in clinical pharmacology. The concept of cytochrome P450 (CYP) enzyme polymorphisms, such as the CYP2D6 ultrarapid metabolizer phenotype leading to increased drug clearance, is a well-documented and clinically critical aspect of pharmacogenetics. The language is objective and the data provided are realistic for drugs like tricyclic antidepressants.\n\nTo confirm internal consistency, the data for the EM reference population are checked. The average steady-state concentration is given by the formula $\\bar{C}_{ss} = \\frac{F \\cdot D}{CL \\cdot \\tau}$. For the EM population, the target concentration is the midpoint of the $100\\text{--}300$ ng/mL window, which is $\\bar{C}_{\\mathrm{ss,EM}} = \\frac{100+300}{2} = 200$ ng/mL. This is equivalent to $0.200$ mg/L. Using the provided EM data:\n$$ \\bar{C}_{\\mathrm{ss,EM}} = \\frac{F \\cdot D_{\\mathrm{EM}}}{CL_{\\mathrm{EM}} \\cdot \\tau} = \\frac{0.50 \\cdot 96 \\text{ mg}}{10 \\text{ L/h} \\cdot 24 \\text{ h}} = \\frac{48 \\text{ mg}}{240 \\text{ L}} = 0.200 \\text{ mg/L} $$\nThe calculated concentration matches the stated target, confirming that the problem's premises are internally consistent and not contradictory. The problem is well-posed and contains all necessary information for a unique solution.\n\n**Step 3: Verdict and Action**\nThe problem is valid. The solution process may proceed.\n\nThe fundamental relationship for the average plasma concentration at steady state ($\\bar{C}_{ss}$) for a drug administered orally is:\n$$ \\bar{C}_{ss} = \\frac{F \\cdot D}{CL \\cdot \\tau} $$\nwhere $F$ is the oral bioavailability, $D$ is the total dose administered over the dosing interval $\\tau$, and $CL$ is the systemic clearance. Our objective is to determine the required dose, $D_{\\mathrm{UM}}$, for the ultrarapid metabolizer patient.\n\nFirst, we establish the target average steady-state concentration, $\\bar{C}_{\\mathrm{ss,UM}}$, for this patient. The specified therapeutic window is $120\\text{--}180$ ng/mL, and the goal is to target the midpoint.\n$$ \\bar{C}_{\\mathrm{ss,UM}} = \\frac{120 \\text{ ng/mL} + 180 \\text{ ng/mL}}{2} = 150 \\text{ ng/mL} $$\nTo ensure dimensional homogeneity in the main equation, we convert this concentration to units of mg/L. Noting that $1 \\text{ mg} = 10^6 \\text{ ng}$ and $1 \\text{ L} = 10^3 \\text{ mL}$:\n$$ 150 \\frac{\\text{ng}}{\\text{mL}} = 150 \\frac{10^{-6} \\text{ mg}}{10^{-3} \\text{ L}} = 150 \\times 10^{-3} \\frac{\\text{mg}}{\\text{L}} = 0.150 \\frac{\\text{mg}}{\\text{L}} $$\nThus, the target concentration is $\\bar{C}_{\\mathrm{ss,UM}} = 0.150$ mg/L.\n\nNext, we determine the systemic clearance for the UM patient, $CL_{\\mathrm{UM}}$. The problem states that this patient's clearance is $3.0$-fold greater than the reference EM clearance of $CL_{\\mathrm{EM}} = 10$ L/h.\n$$ CL_{\\mathrm{UM}} = 3.0 \\times CL_{\\mathrm{EM}} = 3.0 \\times 10 \\text{ L/h} = 30 \\text{ L/h} $$\n\nThe remaining parameters are unchanged: oral bioavailability $F=0.50$ and dosing interval $\\tau=24$ h.\n\nWe now rearrange the steady-state concentration formula to solve for the dose $D_{\\mathrm{UM}}$:\n$$ D_{\\mathrm{UM}} = \\frac{\\bar{C}_{\\mathrm{ss,UM}} \\cdot CL_{\\mathrm{UM}} \\cdot \\tau}{F} $$\nSubstituting the determined values:\n$$ D_{\\mathrm{UM}} = \\frac{(0.150 \\text{ mg/L}) \\cdot (30 \\text{ L/h}) \\cdot (24 \\text{ h})}{0.50} $$\nThe units of liters (L) and hours (h) cancel, leaving the dose in units of mg.\n$$ D_{\\mathrm{UM}} = \\frac{0.150 \\cdot 30 \\cdot 24}{0.50} \\text{ mg} $$\n$$ D_{\\mathrm{UM}} = \\frac{4.5 \\cdot 24}{0.50} \\text{ mg} $$\n$$ D_{\\mathrm{UM}} = \\frac{108}{0.50} \\text{ mg} $$\n$$ D_{\\mathrm{UM}} = 216 \\text{ mg} $$\n\nThe calculated total daily dose is $216$ mg. The problem requires the answer to be expressed to three significant figures, which the value $216$ already satisfies.\n\nA confirmatory check can be performed using proportional reasoning. The dose $D$ is directly proportional to both target concentration $\\bar{C}_{ss}$ and clearance $CL$. The relationship can be expressed as a ratio:\n$$ \\frac{D_{\\mathrm{UM}}}{D_{\\mathrm{EM}}} = \\frac{\\bar{C}_{\\mathrm{ss,UM}} \\cdot CL_{\\mathrm{UM}}}{\\bar{C}_{\\mathrm{ss,EM}} \\cdot CL_{\\mathrm{EM}}} $$\nSolving for $D_{\\mathrm{UM}}$ and substituting the known values ($D_{\\mathrm{EM}}=96$ mg, $\\bar{C}_{\\mathrm{ss,EM}}=200$ ng/mL, $\\bar{C}_{\\mathrm{ss,UM}}=150$ ng/mL, and $CL_{\\mathrm{UM}} = 3.0 \\cdot CL_{\\mathrm{EM}}$):\n$$ D_{\\mathrm{UM}} = D_{\\mathrm{EM}} \\cdot \\left(\\frac{\\bar{C}_{\\mathrm{ss,UM}}}{\\bar{C}_{\\mathrm{ss,EM}}}\\right) \\cdot \\left(\\frac{CL_{\\mathrm{UM}}}{CL_{\\mathrm{EM}}}\\right) = 96 \\text{ mg} \\cdot \\left(\\frac{150}{200}\\right) \\cdot (3.0) = 96 \\cdot 0.75 \\cdot 3.0 \\text{ mg} = 216 \\text{ mg} $$\nThe result is consistent.",
            "answer": "$$\\boxed{216}$$"
        }
    ]
}